Japan Approves Sanofi's Sarclisa SC for Multiple Myeloma, Expanding Global Reach
SNY is trading near its 52-week low of $41.855 (0.8% above the low).
Summary
Japan has approved Sanofi's Sarclisa subcutaneous (SC) formulation for multiple myeloma, following its recent EU approval earlier this month. This expands market access for Sarclisa in a major market, offering a more convenient treatment option for patients compared to intravenous administration. The SC formulation, which could eventually be administered via an on-body injector, aims to improve patient experience and potentially increase market share in Japan's growing multiple myeloma patient population. A regulatory submission for the on-body injector is under review in Japan, and a similar application for Sarclisa SC is pending in the US.
At the time of this announcement, SNY was trading at $42.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $101.3B. The 52-week trading range was $41.86 to $52.68. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.